Evidence map›Paper›PMID 34462287›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.

Erica C Nakajima, Paz J Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S Mishra-Kalyani, Youwei Bi, Hisham Qosa, Jiang Liu, Hong Zhao, Missiratch Biable and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Erica C Nakajima *Center for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland. erica.nakajima@fda.hhs.gov.
Paz J Vellanki *Center for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Erin LarkinsCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Somak ChatterjeeCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Pallavi S Mishra-KalyaniCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Youwei BiCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Hisham QosaCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Jiang LiuCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Hong ZhaoCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Missiratch BiableCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Lauren Tesh HotakiCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0001-9674-8424
Yuan-Li ShenCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Richard PazdurCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Julia A BeaverCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Harpreet SinghCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
Martha DonoghueCenter for Drug Evaluation and Research and Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0003-4493-6399
Center for Drug Evaluation and Research · US

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma (MPM). The approval was based on results from Study CA209743 (CHECKMATE-743), an open-label trial of patients with MPM randomized to receive nivolumab and ipilimumab for up to 2 years (

Indexed as

Drug ApprovalAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansIpilimumabMaleMesothelioma, MalignantNivolumabPleural NeoplasmsRandomized Controlled Trials as TopicTreatment OutcomeIpilimumabNivolumab

Identifiers

PMID34462287
PMCPMC8810571
OpenAlexW3198912637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.